<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618369</url>
  </required_header>
  <id_info>
    <org_study_id>1000040583</org_study_id>
    <nct_id>NCT02618369</nct_id>
  </id_info>
  <brief_title>MR-Guided High Intensity Focused Ultrasound for Pain Management Of Osteoid Osteoma &amp; Benign Bone Tumors in Children and Adults</brief_title>
  <official_title>Magnetic Resonance-Guided High Intensity Focused Ultrasound for Pain Management of Osteoid Osteoma and Benign Bone Tumors in Children and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Philips Sonalleve HIFU system is expected to be efficacious in reducing pain scores in&#xD;
      patients with painful osteoid osteoma and other benign bone tumors, and in reducing their&#xD;
      pain medication usage. No serious adverse effects are expected to result from this treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine if MR-guided high-intensity focused ultrasound&#xD;
      (MR-HIFU) is safe and effective technique for alleviating the pain associated with osteoid&#xD;
      osteoma and other benign bone tumors in paediatric patients and adults(up to age 40 yrs).&#xD;
      This technique meant to be an alternative to the standard-of-care, radiofrequency and&#xD;
      laser-based percutaneous ablation. Safety of the technique will be assessed through&#xD;
      evaluating non-targeted heating using MRI based temperature mapping. and inspecting patients&#xD;
      post treatment for skin burns or other signs of serious adverse events. Efficacy of the&#xD;
      technique will be assessed by evaluating/recording patients observed pain, quality of life,&#xD;
      and pain medication usage both before and up to 6 months following treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain intensity scores from baseline related to the site treated target lesion.</measure>
    <time_frame>2, 7, 14, 30 and 90 days following treatment.</time_frame>
    <description>As measured on the pain diaries before and at day 2, 7, 14, 30 and 90 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in in pain medication usage (NSAIDS, Opioids).</measure>
    <time_frame>2, 7, 14, 30 and 90 days following treatment.</time_frame>
    <description>As noted in pain diaries by patient before and day 2, 7. 14, 30 and 90 days after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoid Osteoma</condition>
  <condition>Benign Bone Tumor</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>MR-HIFU treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.&#xD;
The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR-Guided High Intensity Focused Ultrasound</intervention_name>
    <description>Target treatment of bone lesion using High Intensity Focused Ultrasound</description>
    <arm_group_label>MR-HIFU treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 5-40 years.&#xD;
&#xD;
          -  Able to give informed consent and have parent or guardian give informed consent if&#xD;
             applicable.&#xD;
&#xD;
          -  Weight &lt;140 kg (requirement to fit safely on top of the HIFU table and inside the&#xD;
             MRI).&#xD;
&#xD;
          -  Definitive radiographic &amp; clinical presentation of osteoid osteoma or other benign&#xD;
             tumor lesion(avoiding need for biopsy).&#xD;
&#xD;
          -  Pain specifically at the site of interest target lesion.&#xD;
&#xD;
          -  Pain score for target lesion &gt;/= 4 (indicating at least moderate pain) or an&#xD;
             age-appropriate pain scale.&#xD;
&#xD;
          -  Target lesion is uncomplicated (i.e. no fracture/spinal cord compression/cauda equina&#xD;
             syndrome/soft tissue component).&#xD;
&#xD;
          -  MR-HIFU treatment date &gt;/= 2 weeks from most recent surgical treatment of lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to characterize pain specifically at the site of interest (target lesion).&#xD;
&#xD;
          -  Pregnant/nursing females.&#xD;
&#xD;
          -  Target lesion is complicated (i.e. presence of one of fracture/spinal cord&#xD;
             compression/cauda equina syndrome/soft tissue component).&#xD;
&#xD;
          -  Target lesion &lt; 1cm from neurovascular bundles/bowel/hollow viscera or regions of&#xD;
             cartilage/ bone growth).&#xD;
&#xD;
          -  Target lesion located in skull, spine (excluding sacrum, which is allowed) or sternum.&#xD;
&#xD;
          -  Scar along proposed HIFU beam path.&#xD;
&#xD;
          -  Orthopaedic implant along proposed HIFU beam path or at site of target tissue.&#xD;
&#xD;
          -  Serious cardiovascular, neurological, renal or haematological chronic disease.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Contraindication to general anaesthetic or gadolinium MRI contrast agent.&#xD;
&#xD;
          -  Requirement for general anesthesia for non-HIFU related MRI's.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Drake, FRCSC, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>James Drake</investigator_full_name>
    <investigator_title>Neurosurgeon</investigator_title>
  </responsible_party>
  <keyword>High Intensity Focused Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Osteoma</mesh_term>
    <mesh_term>Osteoma, Osteoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

